Adicet announces poster presentations highlighting adi-270 data at the society for immunotherapy of cancer (sitc) 2025 spring scientific meeting

Redwood city, calif. & boston--(business wire)--adicet bio, inc. (nasdaq: acet), a clinical stage biotechnology company discovering and developing allogeneic gamma delta t cell therapies for autoimmune diseases and cancer, today announced the acceptance of two abstracts for poster presentations at the upcoming society for immunotherapy of cancer (sitc) 2025 spring scientific meeting taking place march 12-14, 2025, in san diego, c.a. details of the poster presentation are as follows: abstract ti.
ACET Ratings Summary
ACET Quant Ranking